Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Total Current Liabilities (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Total Current Liabilities for 7 consecutive years, with $37.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities rose 25.94% to $37.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $37.1 million, a 25.94% increase, with the full-year FY2024 number at $29.1 million, up 53.81% from a year prior.
  • Total Current Liabilities was $37.1 million for Q3 2025 at 4D Molecular Therapeutics, up from $34.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $37.1 million in Q3 2025 to a low of $9.9 million in Q2 2021.
  • A 5-year average of $19.1 million and a median of $16.3 million in 2021 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: fell 13.11% in 2022, then surged 78.72% in 2025.
  • 4D Molecular Therapeutics' Total Current Liabilities stood at $16.3 million in 2021, then fell by 3.72% to $15.7 million in 2022, then increased by 20.47% to $19.0 million in 2023, then soared by 53.81% to $29.1 million in 2024, then increased by 27.3% to $37.1 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Total Current Liabilities are $37.1 million (Q3 2025), $34.7 million (Q2 2025), and $26.9 million (Q1 2025).